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IL-22Progression of chronic obstructive pulmonary disease (COPD) is linked to episodes of exacerbations caused by
bacterial infections due to Streptococcus pneumoniae. Our objective was to identify during COPD, factors of sus-
ceptibility to bacterial infections among cytokine network and their role in COPD exacerbations. S. pneumoniae
was used to sub-lethally challenge mice chronically exposed to air or cigarette smoke (CS) and to stimulate
peripheral blood mononuclear cells (PBMC) from non-smokers, smokers and COPD patients. The immune
response and the cytokine production were evaluated. Delayed clearance of the bacteria and stronger lung
inﬂammation observed in infected CS-exposed mice were associated with an altered production of IL-17 and
IL-22 by innate immune cells. This defect was related to a reduced production of IL-1β and IL-23 by antigen pre-
senting cells. Importantly, supplementation with recombinant IL-22 restored bacterial clearance in CS-exposed
mice and limited lung alteration. In contrastwith non-smokers, bloodNK andNKT cells fromCOPDpatients failed
to increase IL-17 and IL-22 levels in response to S. pneumoniae, in association with a defect in IL-1β and IL-23
secretion. This study identiﬁed IL-17 and IL-22 as susceptibility factors in COPD exacerbation. Therefore targeting
such cytokines could represent a potent strategy to control COPD exacerbation.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic obstructive pulmonary disease (COPD) remains a major
cause of morbidity and mortality worldwide. This will be the third
cause of deaths worldwide in 2020 according to the WHO. COPD is a
lung disorder characterized by progressive and irreversible airﬂow
limitation. Cigarette smoking is a primary risk factor for the develop-
ment of COPD, although other factors, including pollution and genetic
determinants, have been described. Cigarette smoke (CS) chronically
triggers inﬂammatory processes which ultimately alter pulmonaryisease; CS, cigarette smoke; Sp,
, broncho-alveolar lavage; APC,
endritic cells; PBMC, peripheral
ural killer T cells.
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. This is an open access article underbarrier functions and reduce immune defense mechanisms, thus lead-
ing to increased susceptibility to respiratory infections (Agusti et al.,
2003; Barnes and Stockley, 2005; Fletcher and Peto, 1977; Soler et al.,
1999; Soler-Cataluna et al., 2005).
Such infections further alter the clinical status of COPD patients
thereby indirectly causing extensive morbidity and mortality (Soler
et al., 1999). Acute exacerbation of COPD patients is associated with a
greater decline in lung function, enhanced oedema as well as airway
and systemic inﬂammation (Agusti et al., 2003). Amongmajor bacterial
species causing COPD exacerbation are Streptococcus pneumoniae, non-
typeable Haemophilus inﬂuenzae and Moraxella catarrhalis (Sethi and
Murphy, 2008). Cigarette smoking is associated with diminished anti-
bacterial immune responses and delayed clearance of microbial agents
(Drannik et al., 2004). However, it is not well understood how these
alterations are controlled during COPD and why COPD patients are
more susceptible to infections (Soler-Cataluna et al., 2005). Considering
the increasing prevalence of COPD, there is an urgent need to betterthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Characteristics of COPD patients, smokers and non-smoker subjects.
Group COPD Smokers Non smokers
Nb 12 14 14
Sexes (M/F) 11/1 11/3 10/4
Age 59.2 ± 17.1 43.9 ± 4.7 45.5 ± 5.7
Smoking (pack/year) 57 ± 5.9 37.6 ± 5.2 0
FEV1% 51.3 ± 4.1 94.7 ± 1.3 95.3 ± 3.5
PO2 77.1 ± 6.6 ND ND
BODE 3. 1 ± 0.5 ND ND
Body mass index 25.6 ± 1.2 ND ND
VEMS% 56.9 ± 4.6 ND ND
MRC score 1.5 ± 0.31 ND ND
6 MWT 410 ± 34.8 ND ND
Inhaled corticosteroid 4 0 0
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order to propose novel therapeutics (Barnes and Stockley, 2005).
Among the factors orchestrating the anti-bacterial response, Th17
cytokines, including interleukin (IL)-17 and IL-22, play a major role
(Eidenschenk et al., 2014; Ivanov et al., 2013). These cytokines are pro-
duced by various cells of the adaptive and innate immune system. These
include conventional T lymphocytes, natural killer (NK) cells, non-
conventional T cells (such as γδ T cells, NKT cells and invariant
mucosal-associated T (MAIT) cells) and type 3 innate lymphoid cells
(ILC3). Production of Th17 cytokines is strongly dependent on IL-1β,
IL-23 and IL-6 secretion by antigen presenting cells (APC) (Doisne
et al., 2011; Ivanov et al., 2014). Anti-bacterial effects of Th17 cytokines
comprise the induction of antimicrobial peptides and neutrophil
chemoattractants by airway epithelial cells (Aujla et al., 2008; Wolk
et al., 2004). Both IL-17 and IL-22 amplify the granulopoiesis by increas-
ing the expression of G-CSF. In addition, IL-22 plays a central role in the
maintenance of the epithelium integrity by limiting cellular apoptosis
and by favoring repair/regeneration processes (Sonnenberg et al.,
2011).
Since Th17 cytokines playmajor functions in the control of bacterial,
including pneumococcal, outgrowth, we hypothesized that their
production upon respiratory bacterial challenge could be altered in
the context of COPD. Indeed, our data indicate a default in Th17 cytokine
production, especially IL-22, in response to S. pneumoniae in a mouse
model of COPD induced by chronic CS exposure (Pichavant et al.,
2014) and ex vivo in COPD patients. This reduced response was associ-
ated with diminished production of Th17 cytokine inducing factors by
pulmonary APC. Remarkably, administration of recombinant IL-22 in
CS-exposed mice just before the bacterial challenge resulted in acceler-
ated pneumococcal clearance and lowered pulmonary inﬂammation.
Thus, targeting Th17 cytokines might be valuable to limit COPD exacer-
bation due to bacterial infections.
2. Material and Methods
2.1. Mice
Six- to eight-week-old male wild-type (WT) C57BL/6 (H-2Db) mice
were purchased from Janvier (Le Genest-St.-Isle, France). All animal
work conformed to the guidelines of Animal Care and Use Committee
from Nord Pas-de-Calais (agreement no. AF 16/20,090). Mice were
exposed to CS (5 cig/day, 5 days/week) during 12 weeks as previously
described in order to generate a COPD-like disease (Wolk et al., 2004),
or ambient air as control. Six to ten mice were used per group and per
experiment. Experiments were repeated at least 3 times.
2.2. Patients with COPD
Peripheral blood was collected in stable COPD patients (n = 12), in
smokers (without COPD, n = 13)) and in non-smoker healthy controls
(n = 14) (CPP 2008-A00690-55) (see Table 1). Written informed
consent was received from participants prior to inclusion in the study,
according ethics committee on human experimentations. COPD
patients at steady state included subjects with a GOLD score between
2 and 4 and did not received oral corticosteroids.
COPD patients included subjects with a gold score between 2 and 4 and
are matched for age and sex with controls. FEV1%, predicted amount as
a percentage of the forced expiratory lung volume in one second; PO2,
partial pressure of oxygen; BODE: Bode index combining Body mass
index, airﬂow obstruction (VEMS), dyspnea (MRC score) and exercise
(6 minutes walk test [6 MWT]). Results were expressed as
mean± SEM. ND: not determined.
Peripheral blood mononuclear cells (PBMC) were puriﬁed on Ficoll
Paque gradient (GE healthcare). Cells (3 × 106 in 1 ml) were culturedin RPMI1640 (GIBCO, Invitrogen Corporation) supplemented with
10% FCS, 200 U/ml penicillin/streptomycin (PS) and then exposed to
S. pneumoniae (Sp, MOI = 2) or to phytohemagglutinin (1 μg/ml)
(PHA, Difco) as a positive control. After 90 min, antibiotics were added
to stop bacteria growth and supernatants were collected 24 h later.
Cell viability was not affected. Some cells were incubatedwith brefeldin
A (10 μg/ml, Sigma) for 4 h and used for intracellular staining of
cytokines.
2.3. Reagents and Antibodies
Monoclonal antibodies (mAbs) against mouse CD3 (APC-conjugat-
ed), CD5 (FITC-conjugated), NK1.1 (PerCp-Cy5.5–conjugated), TCR-β
(V450-conjugated), CD25 (APC-conjugated), CD69 (Alexa700-conju-
gated), CD11b (V450–conjugated), Ly-6G (APC-Cy7-conjugated), CD8
(V500-conjugated), CD4 (APC-conjugated), CD103 (PE-conjugated),
CD11c (APC-conjugated), CD45 (Q-dot605-conjugated), F4/80 (PerCP-
Cy5.5-conjugated), Siglec F (PE-conjugated), CD64 (APC-conjugated),
CD86 (PE-conjugated), CD40 (PE-conjugated), I-Ab (FITC-conjugated),
IFN-γ (PE-conjugated), IL-17 (APC-conjugated), CD11c (PE-Cy7-conju-
gated), F4/80 (PerCP-Cy5.5-conjugated), CD11b (V450-conjugated)
and CD103 (PE-conjugated) and isotype controls were purchased
from Biolegend (Le Pont de Claix, France). mAbs against human CD
were also used including anti-CD11c, CD14, CD19, CD20 (PE-CF594-
conjugated), CD117, TCRγδ (V450-conjugated), CD4, CD3 (Alexa-700
conjugated), CD8, CD127 (V500 conjugated), CD196, CD3 (BV605 con-
jugated), CD25, CD86 (APC-conjugated), CD56, Vα7.2 (PerCP-Cy5.5
conjugated), TCR Vα24Jα18, CD161 (PE-Cy7 conjugated) and CD45
(APC-H7 conjugated) (BD Biosciences, Biolegend andMyltenyi Biotech)
as well as the Alexa488 anti-IFN-γ, Alexa647 anti-IL-17 (BD Biosci-
ences) and PE anti-IL-22 antibodies (e-Biosciences) and the isotype
controls. 3R4F research cigarettes were purchased from University of
Kentucky (USA) and used to induce COPD like symptoms (Pichavant
et al., 2014). Gating strategy forﬂow cytometry analysis of Th17produc-
ing cells is depicted in Supplemental Fig. 5.
2.4. Primers
Quantitative RT-PCR was performed to quantify mRNA of interest
(Table 2). Results were expressed as mean ± SEM of the relative gene
expression calculated for each experiment in folds (2−ΔΔCt) using
GAPH as a reference, and compared to controls.
2.5. Infection by S. pneumoniae and bacterial counts
Micewere inoculated by the intranasal routewith a clinical isolate of
Sp serotype 1 described elsewhere (Marques et al., 2012). Mice were
anesthetized and administered intranasally with 5 × 104 or 5 × 105
Table 2
Primer sequences for qRT-PCR in mice.
GAPDH F TGCCCAGAACATCATCCCTG
R TCAGATCCACGACGGACACA
DefB2 F AAAGTATTGGATACGAAGCAGAACTTG
R GGAGGACAAATGGCTCTGACA
DefB3 F TGAGGAAAGGAGGCAGATGCT
R GGAACTCCACAACTGCCAATC
Cathelicidin F CAGAGCGGCAGCTACCTGAG
R TCACCACCCCCTGTTCCTT
s100a9 F CACCCTGAGCAAGAAGGAAT
R TGTCATTTATGAGGGCTTCATTT
Il-1b F TCCCCAACTGGTACATCAGCA
R ACACGGATTCCATGGTGAAGTC
Il-6 F AGCCTCCGACTTGTGAAGTG
R CTGATGCTGGTGACAACCAC
Il-12p40 F GACCCTGCCCATTGAACTGGC
R CAACGTTGCATCCTAGGATCG
Il-23p19 F CACCAGCGGGACATATGAA
R CCTTGTGGGTCACAACCAT
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illness and mortality up to 7 days. Bacterial burden in the broncho-
alveolar lavages (BAL), lungs and blood was measured by plating
samples onto chocolate plates. CFU were enumerated 24 h later. In
some experiments, CS-exposed and air mice received recombinant
murine IL-22 (1 μg/mouse; Myltenyi Biotech) by intranasal route 24 h
before Sp challenge.
2.6. Assessment of airway inﬂammation
Micewere sacriﬁced for sampling BAL, lungs, spleen and blood. Total
cell numbers per BAL was determined. For histopathology, lungs were
ﬁxed by inﬂation and immersion in paraformaldehyde (PFA; 4%) and
embedded in parafﬁn. To evaluate airway inﬂammation, lung sections
(4-μm thick) were stained by hematoxylin & eosin.
Pulmonary cells from air or CS-exposed mice were prepared as
previously described (van der Poll and Opal, 2009) and were analyzed
by ﬂow cytometry. To analyze cytokine proﬁles, pulmonary cell sus-
pensions were incubated with phorbol 12-myristate 13-acetate (PMA;
20 ng/ml) and ionomycin (500 ng/ml) for 3 h. Cells were then stained
with appropriate extracellular markers, ﬁxed, permeabilized (BD
Cytoﬁx/cytoperm, BD Bioscience), and incubated with PE-conjugated
mAb against IL-22 (eBiosciences) and Alexa Fluor 647-conjugated
mAb against IL-17 (Biolegend), or control rat IgG1 mAb. Cells were
acquired on a Fortessa cytometer (Becton Dickinson), and analyzed
using the FlowJo software.
Cytokineproductionwas analyzed in total lung cells. For this, 5 × 105
lung cells were seeded on 96-well plates coated or notwith anti-CD3 Ab
(eBiosciences). Forty-eight hours later, supernatants were collected and
analyzed for IFN-γ, IL-17, and IL-22 concentration by ELISA (R&D
Systems).
2.7. Cell sorting and cocultures
Pulmonary cells from Air or CS-exposed mice were prepared as
previously described (van der Poll and Opal, 2009) and were analyzed
by ﬂow cytometry on FACS Aria (Becton Dickinson). CD45+ Siglec F+
alveolar macrophages (AM) and CD45+ Siglec F− Ia+ CD64+ DC wereFig. 1. CS-exposed mice are more susceptible to S. pneumoniae. (2 columns). Mice were chroni
velop symptoms associated to COPD.Micewere then intranasally challengedwith S. pneumonia
CS-exposedmicewasmonitored for aweek after challengewith 5× 104 or 5× 105 CFU of Sp orM
determined in BAL ﬂuids (c). Neutrophils identiﬁed as CD45+ F4/80− CD11b+ Ly6G+ were ana
sections either at 1 or 3 dpi (5× 104 CFU) (e). CFU countswere evaluated in theBAL, lung tissues
*: p b 0.05 or **: p b 0.01 (one-way ANOVA test).sorted (purity N98%). Splenic CD4+ T cells were puriﬁed from Air
mice using magnetic microbeads (Myltenyi Biotech).
Sorted AM and DCwere culturedwith CD4+ T cells in RPMI 10% FCS,
with the ratio 1/10. Supernatants were collected 48 h later to evaluate
IL-17 and IL-22 levels by ELISA.2.8. Statistical Analysis
All the experiments were repeated at least 3 times with 6–10 mice
per group. Results are expressed as the mean ± SEM. Samples were
simply randomized and blindly assigned to the different groups. No
data have been excluded. The statistical signiﬁcance of differences
between experimental groups was calculated by a one-way ANOVA
with a Bonferroni post-test or an unpaired Student t test (GraphPad,
San Diego, CA). The possibility to use these parametric tests was
assessed by checking if the population is Gaussian and the variance is
equal (Bartlett's test). Results with a p value b0.05 were considered
signiﬁcant.
This work was supported by the Institut National de la Santé et de la
Recherche Médicale (Inserm), the Centre National de la Recherche
Scientiﬁque (CNRS) and the Conseil Régional du Nord-Pas de Calais
[StreptoCOPD project; grant number # 13005300]. Funders had no
role in study design, data collection, data analysis, interpretation,
writing of the report.3. Results
3.1. CS-exposed mice display delayed bacterial clearance and exacerbated
inﬂammation upon S. pneumoniae challenge
An experimental model of COPD exacerbation was established in
mice chronically exposed to CS using Sp as the trigger (see Fig. 1a).
Whereas all air mice survived when infected with 5 × 105 CFU, all CS-
exposed mice died within a week. Thus, CS-exposed mice are more
susceptible to pneumococcal infection. In contrast, after administration
of 5 × 104 CFU per mouse, both air and CS-exposed mice survived
(Fig. 1b) and allowed the analysis of airway inﬂammation, remodeling
and immune response.
Relative to air mice, infection was associated with enhanced cellular
recruitment (particularly neutrophils) in the BAL and the lungs of CS-
exposed mice (Fig. 1c–d). Histological examination of lung tissues
showed that inﬂammatory inﬁltrates mainly located in peribronchial
areas and alveolar spaces (Fig. 1e). Moreover, a large thickening of the
alveolar walls was observed in CS-exposed animal mice. In air mice
challenged with bacteria, lung inﬂammation was nearly resolved
3 days post-infection (dpi). Enhanced pulmonary inﬂammatory
response in CS-exposed mice was associated with a higher bacterial
load that peaked at 3 dpi whilst no bacteria were detected in air mice
(Fig. 1e). No bacteria were found in the lungs at 7 dpi. Finally, systemic
pneumococcal dissemination peaked at 3 dpi to decline at 7 dpi. This en-
hanced susceptibility of CS-exposed to Sp was associated to a restricted
defect in anti-microbial peptides, namely for cathelicidin, whereas
levels of DefB-2 and -3 and s100a9 transcripts were similarly increased
in air and CS-exposed (Supplemental Fig. 1).
These data demonstrated that chronic exposure to CS leads to
delayed clearance of Sp, an effect associated with enhanced pulmonary
inﬂammation.cally exposed to air or CS (5 cigarettes/day, 5 days/week) over a period of 12 weeks to de-
e (Sp) to induce COPD exacerbation or with PBS (Mock) as a control (a). Survival of air and
ock (b). Absolute numbers of total cells, macrophages, lymphocytes andneutrophilswere
lyzed in lung tissues 24 h after infection (d). Histological changes were evaluated on lung
andblood at 1, 3 and 7 dpi (f). Data represent asmean±SEM(n=48–80miceper group).
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1690 M. Pichavant et al. / EBioMedicine 2 (2015) 1686–16963.2. CS-exposed mice display a reduced production of Th17 cytokines in
response to S. pneumoniae
To investigate mechanisms involved in enhanced susceptibility to
pneumococcal infection in CS-exposedmice, IL-17 and IL-22 production
was quantiﬁed. Challenge with Sp signiﬁcantly enhanced IL-17 and IL-
22 levels in BAL (Fig. 2a) and lung lysates (data not shown) of air
mice. In marked contrast, Sp infection failed to do so in mice previously
exposed to CS (Fig. 2a). Whilst IL-17 remained undetectable in the
serum after Sp challenge, IL-22 increase was detected in air, but not
CS-exposed, animals (Fig. 2b). IFN-γ levels failed also to increase in
the BAL of CS-exposed mice after Sp challenge (Supplemental Fig. 2a).
Anti-CD3 restimulation of pulmonary cells induced large amounts
of IL-17whatever the animal group and a tendency to higher concentra-
tion was observed in CS-exposed mice (Fig. 2c), as well as IFN-γ (Sup-
plemental Fig. 2b). In contrast, upon CD3 restimulation, pulmonary
cells from CS-exposed animals had a much lower ability to release IL-
22. Collectively, CS-exposed mice have a lower capacity to produce
Th17-type cytokines upon pneumococcal challenge.
We next focused on Th17 cytokine producing cells. Infectionwith Sp
enhanced the number, as well as the activation status (CD69 expres-
sion), of conventional T lymphocytes and NKT cells within lung tissues
of air, but not CS-exposed mice (Supplementary Fig. 2c). A tendency
towards an enhanced number of NK cells was noticed in both animals
groups upon pneumococcal challenge whilst the number of γδ T cells
and Lin-negative cells remained constant (Supplemental Fig. 2c and
data not shown). Pneumococcal challenge of air mice resulted in higher
frequencies of IL-17- and IL-22-producing conventional T cells, NK cells,
NKT-like cells, γδ T cells and Lin-negative cells (Fig. 2d–e and not
shown). In contrast, chronic exposure to CS dramatically reduced the
percentages of pulmonary IL-17-producing NK and NKT-like cells, but
not conventional T cells, γδ T cells and Lin-negative cells observed
after Sp challenge (Fig. 2d–e and data not shown). Percentages of
IL-22-producing conventional T cells, NK cells, NKT-like cells and
Lin-negative cells were also signiﬁcantly diminished in infected CS-
exposed mice, relative to air mice.
Hence, upon pneumococcal challenge, chronic exposure to CS leads
to defective production of Th17-type cytokines by conventional T cells
and innate immune cells.
3.3. CS exposure alters the function of pulmonary APC
We next hypothesized that pulmonary APC could be impacted by
CS exposure to lower the activation of innate and conventional T cells
to bacteria. Indeed, we and others previously reported that chronic
exposure to CS alters pulmonary APC phenotype and functions
(Pichavant et al., 2014; Tsoumakidou et al., 2008). Exposure to a sub-
lethal dose of Sp triggered phenotypic maturation of pulmonary APC,
including alveolar macrophages (AM) and dendritic cells (DC) (CD86
and II+ MHC; data not shown). To analyze their ability to promote
Th17 cytokine production, levels of polarizing cytokines including IL-
1β and IL-23were evaluated ﬁrst in lung lysates (Fig. 3a) and secondary
in isolated pulmonary APC (Fig. 3b and Supplemental Fig. 3). Pneumo-
coccal challenge strongly induced mRNA levels of Il-1b and Il-23p19 in
air but not in CS-exposed mice (Fig. 3a). Sp infection also induced
mRNA levels of Il-1b, Il-6, Il-23p19, but not Il-12p40, in sorted lung DC
and slightly increased the expression of Il-1b and Il-12p40 transcripts
in sorted AM from air mice (Supplemental Fig. 3). In CS-exposed mice,
a defect in Il-1b and Il-12p40 expression was observed in AM, whereas
the expression of Il-23p19 mRNA was undetectable in lung DC. At the
protein level, IL-1β and IL-23 secretion was increased in supernatants
of AM and DC from infected air mice, but not in cells from CS-exposed
mice (Fig. 3b).
To evaluate the capacity of these sorted APC to activate T cells, lung
DC and AM were cultured with isolated splenic CD4+ T cells from air
mice. In these conditions, IL-22 was always undetectable (data notshown). AM (Fig. 3c) and DC (Fig. 3d) sorted from infected air mice
induced signiﬁcant increase in IL-17 production by CD4+ T cells,
whereas antigen-presenting cells from CS-exposed mice were unable
to do so.
These data suggested that the defect in the Th17 response to Sp is
associated with an altered function of pulmonary APC.
3.4. Exogenous IL-22 protects CS-exposed mice from
S. pneumoniae infection
Since IL-17 and IL-22 production is ablated in CS-exposed mice, we
questioned whether IL-17 and IL-22 supplementation by means of
intranasal treatment could improve the outcome of pneumococcal
infection in CS-exposed mice. We have previously demonstrated that
IL-17 was critical in the development of COPD in a mouse model and
higher in COPD patients than in controls (Pichavant et al., 2014). There-
fore, exogenous IL-17 could have some deleterious effects during COPD
exacerbations. We therefore tested the effect of exogenous IL-22 in the
early control of Sp outgrowth and lung inﬂammation. Administration of
recombinant IL-22 prior to bacterial challenge strongly reduced bacteri-
al outgrowth in the lungs and dissemination outside the lungs (Fig. 4a).
While treatment with IL-22 had no effect on neutrophil recruitment
within the lungs, it enhanced the number of activated AM and DC in
CS-exposed mice (Fig. 4b and Supplemental Fig. 4a), other well-
known effector cells against pneumococcus. This process was also asso-
ciatedwith an increasedmobilization of NK andNKT cells in the lungs of
infected COPD mice (Supplemental Fig. 4b). Of interest, administration
of IL-22 resulted in enhanced levels of transcripts encoding defensin
β2 (Defb2) and defensin β3 (Defb3) (Fig. 4c), both anti-microbial
peptides playing a role in Sp clearance. Finally, IL-22 treatment also
strongly reduced the lung lesions associated with Sp infection, namely
the thickening of the alveolar walls and the inﬂammatory inﬁltrate
in CS-exposed animals (Fig. 4d). This improved clearance of Sp in CS-
exposed mice was also associated with higher IL-17 and IFN-γ produc-
tion by lung cells (Supplemental Fig. 4c).
Together, recombinant IL-22 administration can compensate for the
lack of Th17-associated cytokines in CS-exposed mice to restore anti-
pneumococcal defenses.
3.5. COPD patients showed impaired Th17 cytokine production in response
to S. pneumoniae
To evaluate whether COPD status modulates the response to Sp,
PBMCs were isolated from 3 different groups: non-smoker healthy con-
trols, smokers and COPD patients, and were stimulated with Sp. Levels
of IL-17 and IL-22 were evaluated in PBMC supernatants. Resting
PBMC exhibited similar levels of cytokines in the three groups (Fig.
5a). Exposure to Sp expectedly increased IL-22 and, to a lesser extent,
IL-17 production in the non-smoker and smoker groups, but had no
effect on cytokine production in COPD patients. The response to PHA
was also partially altered in COPD patients, in contrast to the other
two groups (data not shown).
We next looked at the cellular sources of IL-17 and IL-22, focusing on
conventional T cells, NK cells, NKT cells, γδ T cells, mucosal-associated
invariant T (MAIT) cells and Lineage-negative cells (Fig. 5b and Supple-
mentary Fig. 5). In the non-smoker group, bacteria increased the
proportion of IL-17-producing cells (in particular Lin−, NK and NKT
cells), IL-22-producing cells (mainly NK and NKT cells) and MAIT cells
(not shown). In contrast, the stimulation with Sp did not signiﬁcantly
amplify the proportion of cells producing these cytokines in NK, NKT
and Lin− cells (Fig. 5b) as well as in MAIT cells (data not shown) from
COPD patients. In smokers, IL-17 production induced by Sp was also
impaired in these three cell types, whereas IL-22 expression was only
reduced in NK cells. No modiﬁcation of the percentage of cytokine+
cells was detected among the three groups of patients for γδT and
CD4/CD8+ T cells (data not shown). This defective production of IL17
Fig. 2. CS-exposed mice exhibit a defective immune response to S. pneumoniae. (2 columns). Mice were chronically exposed to air or CS over a period of 12 weeks and then intranasally
challengedwith 5× 104 CFU of S. pneumoniae (Sp) orwith PBS (Mock). IL-17 and IL-22 levelswere evaluated inBALﬂuids (a), blood (b) and in the supernatants of restimulatedpulmonary
cells without (NS) or with anti-CD3 Ab (c). IL-17 and IL-22 producing cells were identiﬁed by intracellular staining among pulmonary NK cells (CD45+ TCRβ− NK1.1+), NKT-like cells
(CD45+ TCRβ+ NK1.1+), T cells (CD45+ TCRβ+ NK1.1−) and Lin-negative cells (CD45+ CD3− CD11c− CD11b− CD45Rb− NK1.1− CD90.2+ CCR6+) cells (d and e). We have reported
representative dot blot of the selected sub-populations and percentages of cytokine+ cells among the respective cell population are represented (c). The mean percentage of IL-17+
and IL-22+ cellswas calculated forNK,NKT and Lin− cells (d). Results are expressed asmean±SEM (n=48–80mice per group). One representative experiment out of three independent
ones is shown concerning intracellular staining. *: p b 0.05 vs controls (one-way ANOVA test).
1691M. Pichavant et al. / EBioMedicine 2 (2015) 1686–1696and IL-22 was probably linked to the lower production of IL-1β and IL-
23 by PBMC from COPD patients (Fig. 5C).These data showed that the
blood innate immune cells from COPD patients displayed an altered
Th17 cytokine response to Sp.4. Discussion
Infection with Sp is one of the main factors responsible for COPD
exacerbation (Gaschler et al., 2007; van der Poll and Opal, 2009).
Fig. 3. CS-exposedmice exhibited a defective response of pulmonary APC to S. pneumoniae. (1.5 columns). Mice were chronically exposed to air or CS over a period of 12weeks and then
intranasally challengedwith 5 × 104 CFU of S. pneumoniae (Sp) orwith PBS (Mock). Il-1b and Il-23mRNA levelsweremeasured in lung tissues 24 h post-infection (a). CD45+ Siglec F+ AM
and CD11c+ Ia+ CD64+ DCwere sorted by ﬂow cytometry 24 h post-infection. IL-1β and IL-23 levels were evaluated by ELISA in supernatants 24 h later (b). Cocultures were performed
between sorted AM (c) or DC (d) and splenic CD4+ T cells puriﬁed from air mice. Supernatants were collected 48 h later and levels of IL-17 were evaluated by ELISA. Data represent
mean ± SEM (n = 6–10 mice per group per experiment). One representative experiment out of three ones is shown concerning cell sorting and cocultures with T cells.
1692 M. Pichavant et al. / EBioMedicine 2 (2015) 1686–1696In our mouse model mimicking COPD, Sp challenge resulted in greater
lung inﬂammation and tissue remodeling, and therefore an exacerba-
tion of the disease. Combined exposure to CS and SEB resulted in a
raised number of lymphocytes and neutrophils, epithelial remodeling
and over-production of IL-17 (Huvenne et al., 2011). Gaschler et al.
used H. inﬂuenza to exacerbate COPD and demonstrated that the
bacterial burden observed in COPD mice was mainly due to a skewed
inﬂammatory mediator expression, probably in AM (Gaschler et al.,
2009). Innate immunity associated with the recruitment of
competent AM and neutrophils is crucial in the early phase ofnatural anti-pneumococcal host defense and particularly in bacterial
clearance (Clement et al., 2008). Such a pattern was observed in our
model despite a defective clearance of the pathogen in CS-exposed
mice.
Indeed, we observed some important modiﬁcations in the activa-
tion of APC from CS-exposed mice, but also in not conventional lym-
phocytes. Major cellular sources of IL-17 and IL-22, described as NK,
NKT, ILC in mice and humans (Colonna, 2009; Liang et al., 2006;
Sonnenberg et al., 2012; Van Maele et al., 2010), failed to produce
higher levels of Th17 cytokines in response to Sp in CS-exposed
Fig. 4. Exogenous IL-22 improves the clearance of S. pneumoniae in CS-exposedmice. (1.5 columns). Mice were chronically exposed to air or CS over a period of 12 weeks and then intra-
nasally challenged with 5 × 104 CFU of S. pneumoniae (Sp) or with PBS (Mock). Recombinant murine IL-22 was intranasally administered the day before Sp infection. CFU counts were
evaluated in BAL, lung tissues and blood (a). Percentages of neutrophils (identiﬁed as CD45+ F4/80− CD11c− Ly6G+ CD11b+), AM and DC among CD45+ cells were analyzed in lung
tissues from infected CS-exposed mice treated or not with rmIL-22 (b). Anti-microbial peptide mRNA levels were analyzed in lung tissues 3 dpi (c). Histological changes were evaluated
at 3 dpi (d). Data represent mean ± SEM (n= 24–40 mice per group). *: p b 0.05 vs controls (one-way ANOVA test).
1693M. Pichavant et al. / EBioMedicine 2 (2015) 1686–1696mice whereas only the production of IL-22 was altered in conven-
tional T cells. According to the implication of such cells in
the protection against Sp (Marques et al., 2012; Clement et al.,
2008; Van Maele et al., 2010), this suggest that this defect might be
an important determinant of bacterial susceptibility during COPD.
In contrast, the activation of conventional T cells, MAIT and γδT
cells was not clearly modiﬁed during COPD.Thedefective activation of conventional T cells and some innate pop-
ulations could be explained by the alteration of pulmonary APC, as pre-
viously reported in CS-exposed mice (Pichavant et al., 2014; Kroening
et al., 2008). Indeed expression of pro-Th17 cytokines, such as IL-1β
and IL-23 (Mucida and Salek-Ardakani, 2009), was decreased both in
lung AM and DC from infected CS-exposed mice. IL-23 plays a key role
in the clearance of the bacteria and the production of Th17 cytokines
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1695M. Pichavant et al. / EBioMedicine 2 (2015) 1686–1696by ILC (Van Maele et al., 2014). IL-23 is also needed for IL-17 expression
by others immune cells like NKT and γδ T-cells (Clement et al., 2008).
Therefore, APC from CS-exposed mice cannot correctly educate the
T cells and other innate cells to respond to Sp. Such a defective production
of IL-1β and IL-23 was also observed in COPD patients in response to Sp.
(Kroening et al., 2008).Altogether, during COPD, the reduced production
of IL-17 and IL-22 by conventional T cells and other innate cells might
result from a deﬁcient IL-1β and IL-23 synthesis by DC in response to Sp.
Functionally, IL-17 and IL-22have been reported as essential factors in
anti-bacterial defenses. During infection, the early production of IL-22 by
innate immune cells is crucial for host protective immunity (Aujla et al.,
2008; Graham et al., 2011; Zheng et al., 2008) including a role in chemo-
taxis and tissue repair (Wolk et al., 2004; Zheng et al., 2008; Eyerich et al.,
2010; Kolls et al., 2008; Sonnenberg et al., 2010;Witte et al., 2010). It has
been recently shown that IL-17A is required for NTHi-exacerbated pul-
monary neutrophilia induced by cigarette smoke although the role of
IL-22was not evaluated (Roos et al., 2015). Moreover, IL-17 and IL-22 in-
duced the production of anti-microbial peptides (including β-defensins,
S100A7-9, Reg3β and Reg3γ) important in the containment of pathogens
(Zheng et al., 2008; Kolls et al., 2008; Sonnenberg et al., 2010; Cash et al.,
2006). In our report, the defective production of IL-22 in CS-exposedmice
to Spwas not associated to an impaired production of these antimicrobial
peptides as previously reported in COPD patients (Pace et al., 2012). Nev-
ertheless, opposite results have been reported suggesting that the levels
of antimicrobial peptide expression were insufﬁcient to control the
higher bacterial load both inCOPDpatients andmice.We can also suspect
that bacterial susceptibility in infected CS-exposed mice was not solely
related with the defective production of cathelicidin, an IL-22 indepen-
dent peptide involved in defense against Sp (Felgentreff et al., 2006). In-
terestingly, local administration of rmIL-22 ampliﬁed β-defensin levels in
the lungs and a competent immune response, allowing Sp clearance in
CS-exposedmice. No impact on neutrophil inﬂuxwas observed in infect-
ed CS-exposed mice, suggesting that the effect of this cytokine is mostly
related with cell priming to efﬁciently kill the bacteria and/or the release
of anti-microbial peptides. In these settings, the preventive role of IL-22
on lung injury is potentially linked to its complementary action on the in-
duction of antimicrobial peptides, the activation of immune cells (includ-
ing neutrophils) and in the maintenance of the epithelial barrier (Kumar
et al., 2013). In infected CS-exposed animals, treatment with rmIL-22 re-
sults in an efﬁcient resolution and to the preservation of lung tissue after
infection, as previously reported in inﬂammatory models (Liu et al.,
2009). The balance between IL-17 and/or IL-22 expression has been
found to contribute to either the pro-inﬂammatory or tissue-protective
phases of lung defense, depending on the context (Liang et al., 2006;
Eyerich et al., 2010; Sonnenberg et al., 2010). In our model, a protective
role for IL-17 cannot be excluded (Lu et al., 2008), since the production
of IL-17 was also defective in CS-exposed mice and patients in response
to Sp. However, IL-17 is implicated in COPD pathogenesis. During COPD
exacerbation, this cytokine has no effect on lung bacterial load and pro-
motes the neutrophil recruitment which is potentially deleterious (Roos
et al., 2015).
Alteration of the innate immune response to bacterial infection is a
key determinant in the COPD course. It is now well recognized that
respiratory infections are important in the induction, progression and
exacerbation of the disease. Here we identiﬁed the IL-22 defect as a
key factor in COPD exacerbations, both in patients and in the murine
model. This alteration related to deﬁcient activation of lymphocytes by
APC offers hints for the development of novel therapeutic strategies in
COPD exacerbations. Thereby, we propose IL-22 as a promising target
in the treatment and/or the prevention of COPD exacerbations. Restor-
ing this defective cytokine response could represent an ideal therapyFig. 5. COPD patients have a defective cytokine response to S. pneumoniae. (1.5 columns). Levels
smoker subjects (n= 14), healthy smokers (n=14) and COPD patients (n= 12) (a). In paralle
Lin− (CD11c− CD14− CD19− CD20−) cells, NK cells and NKT cells (b). Levels of IL-1β and IL-23
healthy smokers and COPD patients (c). Data represent mean ± SEM. *: p b 0.05 versus mediuto build a competent immune response against pathogens in COPD
patients, and to limit the consequences of exacerbation of the disease.
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